$2.41
▼ $-0.12
(-4.74%)
Vol 1.3M
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$170.3M
ROE
-123.0%
Margin
-156.0%
D/E
16.65
Beta
0.65
52W
$1–$3
Wall Street Consensus
13 analysts · Apr 20261
Strong Buy
1
Buy
6
Hold
3
Sell
2
Strong Sell
15.4%
Buy Rating
Price Chart
Similar Stocks
TARA
Protara Therapeutics Inc
$275.2M
CCCC
C4 Therapeutics Inc
$185.1M
ABEO
Abeona Therapeutics Inc
P/E 3.5
$285.6M
EDIT
Editas Medicine Inc
$200.1M
TLSI
TriSalus Life Sciences Inc
$348.8M
CHRS
Coherus Oncology Inc
P/E 1.1
$171.6M
ALXO
ALX Oncology Holdings Inc
$61.3M
TENX
Tenax Therapeutics Inc
$76.1M
Earnings
Beat rate: 100.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.39 | $-0.34 | +$0.05 |
| Sep 2025 | $-0.42 | $-0.34 | +$0.08 |
| Jun 2025 | $-0.47 | $-0.30 | +$0.17 |
| Mar 2025 | $-0.49 | $-0.41 | +$0.08 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | $54.2M | $3.7M | $7.9M | $3.3M | $6.2M |
| Net Income | -$2.1M | -$40.5M | -$30.5M | -$34.7M | -$37.3M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -112.1% | -112.1% | -112.1% | -112.1% | -123.0% | -123.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -387.7% | -142.1% | -142.1% | -142.1% | -156.0% | -156.0% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 13.40 | 13.40 | 13.40 | 13.40 | 16.65 | 16.65 |
| Current Ratio | 3.78 | 3.78 | 3.78 | 3.78 | 3.76 | 3.76 |
Key Ratios
ROA (TTM)
-27.5%
P/S (TTM)
2.47
P/B
1.5
EPS (TTM)
$-1.07
CF/Share
$-1.58
Rev Growth 3Y
-21.4%
52W High
$3.40
52W Low
$0.87
$0.87
52-Week Range
$3.40
Financial Health
Free Cash Flow
-$41.7M
Net Debt
-$29.6M
Cash
$65.8M
Total Debt
$36.2M
As of Dec 31, 2025
How does ALEC compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ALEC valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
2.5
▼
81%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
1.5
▼
41%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ALEC profitability vs Biotechnology peers
ROE
-123.0%
▼
83%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-156.0%
▲
46%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-27.5%
▲
41%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
ALEC financial health vs Biotechnology peers
D/E ratio
16.7
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
3.8
▼
15%
below
peers
(4.4)
vs Peers
vs Industry
In line
Beta
0.7
▼
33%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
ALEC fundamentals radar
ALEC
Peer median
Industry
ALEC profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ALEC vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
ROSENTHAL ARNON
Chief Executive Officer · Mar 13
116246 shs
BERKLEY NEIL LINDSAY
Chief Financial Officer · Mar 13
54600 shs
WONG-SARAD GRACE
Officer · Mar 10
1000 shs
WONG-SARAD GRACE
Officer · Mar 03
3367 shs
BERKLEY NEIL LINDSAY
Chief Financial Officer · Mar 02
29649 shs
WONG-SARAD GRACE
Officer · Mar 02
8071 shs
ROSENTHAL ARNON
Chief Executive Officer · Mar 02
81864 shs
WONG-SARAD GRACE
Officer · Feb 26
4079 shs
Last 90 days
Top Holders
Top 5: 28.53%TCG Crossover Management, L…
9.06%
$20.0M
Blackrock Inc.
6.48%
$14.3M
Vanguard Group Inc
6.26%
$13.8M
Foresite Capital Management…
3.52%
$7.8M
Merck & Co., Inc.
3.21%
$7.1M
As of Dec 31, 2025
Latest News
No related news yet